The Neurodegeneration Imaging Group is internationally recognised for its clinical research into neurodegenerative diseases. Using imaging technology such as positron emission tomography (PET) and magnetic resonance imaging (MRI), this research aims to improve the likelihood of early diagnoses and track the progression of neurodegenerative diseases. These include Parkinson’s disease, atypical Parkinsonism, Alzheimer’s disease and Huntington’s disease, as well as a range of other conditions.
Neurodegenerative diseases place a heavy burden on healthcare around the world and are ranked as one of the leading causes of disability and death. The research of the Neurodegeneration Imaging Group (NIG) tracks the outcome measures for clinical trials on disease-modifying agents and works in collaboration with other national and international groups to deepen our understanding of the science.
A Talented Group of Passionate Professionals
Composed of well-educated clinicians, diligent students and outstanding researchers, the NIG provides an ideal environment for furthering the development of clinical and research skills in the neurodegenerative disorders field. The group encourages professional development and facilitates access to a range of projects into movement disorders, helping professionals to hone their skills in data collection, analysis and review. These projects allow professionals to improve their research capabilities and planning.
As well as ongoing studies, the NIG runs weekly research meetings that give professionals the opportunity to discuss clinical cases of interest and emerging topics in the field of research into neurodegenerative disorders. Clinics run by knowledgeable clinicians also enable professionals to deepen their understanding of the disorders and develop their clinical skills, fostering a sense of international collaboration and laying the groundwork for a positive future.
Areas of Focus
Headed by Professor Marios Politis, the NIG develops and conducts new projects into the diagnosis, progression and identification of original molecular targets for pharmacotherapy in neurodegenerative disorders. It investigates aetiology and pathophysiology and combines PET and MRI imaging with clinical observation. By monitoring the brain’s responses to both traditional and new forms of treatment, the NIG looks to improve outcomes for those affected by neurodegenerative disorders.
The NIG’s range of current studies is far-reaching and aims to deepen our understanding of Parkinson’s disease and motor neurone disease, among others. The NIG looks for suitable candidates, those with a diagnosis of particular conditions who also fit specific sets of criteria, to further the development of new medications and assist in delaying the progression of symptoms caused by these diseases.